Pontaq - Quick Bytes

  Evera , a Paris-based EV subscription startup, has secured €2 million in funding from Groupe Magellim, Newfund NAEH Innopy, and existing investors. This investment aims to expand Evera's operations across France and enhance its services for businesses transitioning to electric fleets. Evera offers flexible EV subscriptions, including reconditioned vehicles, with commitments ranging from 9 to 40 months. Their proprietary platform enables intelligent fleet management, providing insights into consumption data, battery status, and maintenance needs. By addressing financial and operational constraints, Evera empowers companies to adopt electromobility without compromising flexibility or increasing operational costs. #ElectricMobility #SustainableTransport #EVFleets #BusinessInnovation | Pontaq

  OakNorth's acquisition of Michigan-based Community Unity Bank (CUB) signifies a pivotal step in its US expansion strategy. Since entering the US market in mid-2023, OakNorth has lent over $700 million to lower mid-market businesses, addressing the funding gap left by recent bank collapses. This acquisition enhances OakNorth's capacity to serve US businesses, leveraging CUB's local expertise and strong community ties. For Pontaq , this move underscores the value of strategic acquisitions in scaling operations and entering new markets, aligning with our investment philosophy of fostering cross-border growth and innovation. #OakNorth #CommunityUnityBank #USExpansion #StrategicAcquisition #PontaqPerspective

  Maxion Therapeutics has secured a $72 million Series A funding round, underscoring the biotech sector's robust growth. This investment, led by General Catalyst with participation from British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital, and BGF, highlights the industry's commitment to pioneering technologies. Maxion's proprietary KnotBody® platform aims to address ion channel- and GPCR-driven diseases, offering potential breakthroughs in treating conditions like atopic dermatitis and inflammatory bowel disease. Such advancements align with our mission at Pontaq to support and invest in transformative technologies that redefine healthcare paradigms. #BiotechInnovation #HealthcareAdvancements #VentureCapital #PontaqInsights

  ​ Lisbon-based Biocol Labs , established in 2015 as a spin-off from a family-run laboratory founded in 1977, positions itself as a "post-chemical pharmacy." The company focuses on developing plant-based, science-driven remedies to address health needs unmet by traditional healthcare. Their philosophy emphasizes a balanced approach, integrating the strengths of both natural and chemical medicine. This strategy has enabled Biocol Labs to expand across Europe and into markets where natural medicine remains integral to healthcare, such as Japan and certain parts of Asia. #HealthTech #NaturalMedicine #BiocolLabs #PostChemicalPharmacy #InnovationInHealthcare | Pontaq